General Biotechnology

Your 2-year LOE window is a 5-year death march. The real pharmaceutical patent cliff timeline.
The industry keeps getting this wrongand its costing companies time, money, and leverage.
For years, executives have spoken about a neat, two-year runway bet…

Patent thickets arent just a legal nuisancetheyre a market mechanism that quietly delays the moment generics and biosimilars can compete.
Heres the part most people miss: the expiration date you see in headlines is often not the same date that decides …

The Purple Book Was Never Designed to Answer the Question Drugmakers Actually Ask
For anyone trying to assess biosimilar competition, the Purple Book is often the first stop.
It is also where many patent strategies begin to go wrong.
The FDAs Purple Bo…

The next billion-dollar patent fight in pharma may not be over a drug. It may be over the test that determines who gets it.
For years, pharmaceutical companies treated diagnostics as adjacent to the main event: useful for clinical development, importan…

The next billion-dollar drug may not be protected by a better molecule. It may be protected by the device that delivers it.
For decades, pharmaceutical companies have treated drug patents as the center of their commercial defense: composition of matter…

Orphan-Drug Exclusivity vs. Patent: Who Actually Wins the Market War?
A drug can lose its patentand still keep competitors out.
That is the strategic tension at the heart of rare-disease pharmaceuticals. Companies often treat patents and orphan-drug ex…

Common Side Effects in Pediatric Patients Enbrel (etanercept) in children, approved for polyarticular juvenile idiopathic… https://www.Drugchatter.com/chat/56349/what-are-the-side-effects-of-enbrel-in-children/

What is the generic name alprostadil? Alprostadil is the generic name for a medication that is a man-made… https://www.Drugchatter.com/chat/5915/alprostadil-generic-name/

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the hardest part isnt always the active ingredientits the moat built around it.
For years, the industry has focused on primary pat…